Keyphrases
Adrenocorticotropic Hormone
33%
Angiogenic
11%
Bevacizumab
75%
Bevacizumab Therapy
33%
Brain Development
33%
Brain Tumor Microenvironment
13%
Brainstem
22%
Cell Expansion
11%
Cell-based Medicine
11%
Confidence Interval
18%
Copeptin
33%
Developmental Neuroscience
11%
Faculty of Health Sciences
11%
Genetic Variation
33%
GeoMx
11%
Glioblastoma
99%
Glioblastoma Cell Lines
11%
Glioma
38%
Glucagon
33%
Glucagon Receptor
12%
Growth Hormone
33%
Hazard Rate
33%
Hazard Ratio
33%
High-plex
11%
ICOS Ligand
33%
Immune Regulation
33%
Immunoreactivity
15%
Indusium Griseum
11%
Interleukin-6
33%
Interleukin-8
33%
Model Choice
16%
Neurological Diseases
11%
Neuron Cells
11%
Newly Diagnosed Glioblastoma
44%
Olfactory Bulb
11%
Overall Survival
46%
Pituitary
33%
Prognostic Biomarker
33%
Prognostic Value
33%
Progression-free Survival
19%
Radial Glial Cells
33%
Recurrent Glioblastoma
52%
Regional Heterogeneity
11%
Renin-angiotensin System Inhibitors
33%
Spatiotemporal Difference
11%
Systemic Immune Response
33%
Tumor Microenvironment
13%
Vascular Endothelial Growth Factor
33%
WHO Grade II
13%
YKL-40
100%
Neuroscience
Adrenocorticotropic Hormone
33%
Angiogenesis Inhibitor
16%
Apolipoprotein
11%
Argipressin
8%
Astrocytoma
5%
Bevacizumab
66%
Bovine Somatotropin
33%
Brain Development
11%
Brain Tumor
38%
Brainstem
22%
Cell Expansion
11%
Cell Line
11%
Cell Migration
11%
Central Nervous System
11%
Cerebellar Cortex
11%
Cerebellum
11%
Copeptin
33%
Developmental Neuroscience
11%
Entorhinal Cortex
11%
Genetic Variation
33%
Glial Cells
11%
Glucagon
33%
Glucagon Receptor
12%
Glycoprotein
6%
Growth Hormone Treatment
33%
Immunotherapy
16%
Inducible T Cell Costimulator Ligand
33%
Indusium griseum
11%
Interleukin 6
33%
Interleukin 8
33%
Nervous System Disorder
11%
Olfactory Bulb
11%
Oligodendrocyte
5%
Placebo
13%
Radial Glial Cell
33%
Radiation Therapy
6%
Temozolomide
6%
Vascular Endothelial Growth Factor
16%
Vasculotropin A
33%
Vasculotropin Antibody
16%
Medicine and Dentistry
Angiogenesis Inhibitor
6%
Argipressin
8%
Bevacizumab
13%
Biological Marker
37%
Brain Tumor
18%
Clinical Study
6%
Clinical Trial
6%
Copeptin
33%
Corticotropin
33%
Ganglioglioma
38%
Genetic Variation
33%
Glioblastoma
92%
Glioblastoma Cell Line
9%
Glucagon
33%
Glucagon Receptor
12%
Growth Hormone
33%
Hazard Ratio
23%
Hypophysis Function
33%
Immune Disorder
8%
Immunomodulation
33%
Immunotherapy
6%
Inducible T Cell Costimulator Ligand
33%
Interleukin 6
33%
Interleukin 8
33%
Neoplasm
11%
Overall Survival
33%
Secretion (Process)
13%
Targeted Therapy
6%
Tumor Microenvironment
24%
Univariate Analysis
7%
Vasculotropin
6%
Vasculotropin A
33%
Vasculotropin Antibody
6%
